Alpha¹ by KaimenConfidential

Kaimen Rigor review

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, Gohil S, Paneesha S, Pettitt A, Eyre T, Fox CP, Forconi F, Kennedy B, Balotis C, Pemberton N, Sheehy O, Gribben J, Elmusharaf N, Gatto S, Preston G, Schuh A, Walewska R, Duley L, Webster N, Dalal S, Rawstron A, Howard D, Hockaday A, Jackson S, Greatorex N, Bell S, Stones D, Brown JM, Patten PEM, Hillmen P, UK CLL Trials Group

DOI: 10.1056/NEJMoa2504341
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-21

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/f505727f-e41f-44bd-b1d5-f41acf0b2df1 is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint for the ibrutinib-venetoclax vs ibrutinib comparison is undetectable measurable residual disease (uMRD) in bone marrow, a surrogate biomarker. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD) nor cite validated evidence linking uMRD to clinical outcomes in this context. Although the trial also reports progression-free and overall survival as secondary endpoints, the primary efficacy claim for this comparison is based on uMRD.
“The primary endpoint for ibrutinib-venetoclax vs ibrutinib was uMRD (sensitivity 10-4) in BM at two years after initiation of therapy”
Find in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit13 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase III randomized trial with rigorous design, clear reporting of demographics, ethics, and statistical methods. The main weaknesses are the absence of a data availability statement, lack of explicit statistical software identification, and minor copyedit issues including an internal inconsistency in death counts and impossible percentages in supplementary tables.

Both reviewers agreed on all dimensions and study type (interventional). The statistics verification recomputed 5 tests consistently, but coverage is limited to tests with test statistics/df or effect estimates with CIs; threshold-only p-values and exact p-values were not machine-verified. The integrity check flagged an internal contradiction in death counts and impossible percentages in supplementary tables, which are not reflected in the dimension scores but are noted as action items.

Numerical inconsistencies

2 findings · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed
Mathematically impossible statisticAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: uMRD in BM within 2 years, ibrutinib-venetoclax vs FCR (172/260 vs 127/263).
“172/260 ibrutinib-venetoclax (66.2%), 127/263 FCR (48.3%) (p<0.001)”
Find in source
Taken as given: The numbers 172 and 260 are the event count and group total for ibrutinib-venetoclax.; The numbers 127 and 263 are the event count and group total for FCR.; The test is a two-sided chi-square test on the 2x2 table.
Method: Pearson chi-square test on the 2x2 table (172, 88, 127, 136).
How we recomputed it: pChi2x2(172, 88, 127, 136)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 1
Primary endpoint: uMRD in BM within 2 years, ibrutinib-venetoclax vs ibrutinib (172/260 vs 0/263).
“172/260 ibrutinib-venetoclax (66.2%), 0/263 ibrutinib (0%) (p<0.001)”
Find in source
Taken as given: The numbers 172 and 260 are the event count and group total for ibrutinib-venetoclax.; The numbers 0 and 263 are the event count and group total for ibrutinib.; The test is a two-sided chi-square test on the 2x2 table.
Method: Pearson chi-square test on the 2x2 table (172, 88, 0, 263).
How we recomputed it: pChi2x2(172, 88, 0, 263)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Powered secondary endpoint: PFS HR for ibrutinib-venetoclax vs FCR (0.13, 95% CI 0.08-0.21).
“Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR”
Find in source
Taken as given: The HR is a ratio (log scale).; The CI is a 95% confidence interval.; The p-value is two-sided.
Method: Compute p-value from the HR and 95% CI using the normal approximation on the log scale.
How we recomputed it: pCI(0.13, 0.08, 0.21, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Powered secondary endpoint: PFS HR for ibrutinib-venetoclax vs ibrutinib (0.29, 95% CI 0.17-0.49).
“HR for progression-free survival (ibrutinib-venetoclax vs. ibrutinib) was 0.29 (95%CI, 0.17 to 0.49; P<0.001)”
Find in source
Taken as given: The HR is a ratio (log scale).; The CI is a 95% confidence interval.; The p-value is two-sided.
Method: Compute p-value from the HR and 95% CI using the normal approximation on the log scale.
How we recomputed it: pCI(0.29, 0.17, 0.49, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewer 2
HR for OS ibrutinib-venetoclax vs FCR
“HR for overall survival was: 0.26 (95% CI, 0.13 to 0.50) for ibrutinib-venetoclax vs FCR”
Find in source
Taken as given: The HR is 0.26 with 95% CI 0.13 to 0.50.; The CI is two-sided at 95%.; The p-value is two-sided.
Method: Recomputed p from HR and CI using the normal approximation for the log hazard ratio.
How we recomputed it: pCI(0.26, 0.13, 0.50, 1)

lowinternal contradiction
The abstract reports 76 deaths (39 FCR, 26 ibrutinib, 11 ibrutinib-venetoclax), but the Results section reports 11 (4.2%) ibrutinib-venetoclax, 26 (9.9%) ibrutinib, and 39 (14.8%) FCR deaths, which sums to 76. However, the Safety section states 'Eleven deaths were seen in participants treated with ibrutinib-venetoclax, 25 with ibrutinib and 37 with FCR', which sums to 73 and conflicts with the earlier counts.
Eleven deaths were seen in participants treated with ibrutinib-venetoclax, 25 with ibrutinib and 37 with FCR
Resultsreviewer’s wording
lowimpossible statistic
In Supplementary Table S20, the percentage for 'Other' in the 4-5 years column is 115.2%, which exceeds 100% and is impossible for a proportion.
53 (115.2%)
Table S20reviewer’s wording

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

partialReviewer 1
MRD-guided ibrutinib-venetoclax is more durable than fixed-duration therapy.
The paper compares to historical fixed-duration trials, but this is a cross-trial comparison with caveats.
Evidence: Discussion states MRD responses are more durable than reported in fixed-duration ibrutinib-venetoclax, but no direct comparison is made.
In FLAIR, MRD responses are more durable than reported in fixed-duration ibrutinib-venetoclax, possibly due to the personalized approach and longer exposure to ibrutinib-venetoclax.
Discussion ¶1reviewer’s wording
partialReviewer 2
MRD-guided ibrutinib-venetoclax is more effective than continuous BTK inhibitors.
The claim is supported by cross-trial comparisons, but the paper acknowledges the need for prospective head-to-head comparison.
Evidence: The discussion compares results to other trials but states 'Prospective comparison of the ibrutinib-venetoclax time-limited treatment duration vs continuous BTK inhibitors is needed to definitively address the relative activity.'
With the caveats of cross-trial comparisons, the results from MRD-guided ibrutinib-venetoclax suggests improved survival outcomes over continuous BTK inhibitors.
Discussion ¶3reviewer’s wording
supportedReviewers 1, 2
Ibrutinib-venetoclax leads to higher rates of uMRD compared to ibrutinib alone or FCR.
The primary endpoint data directly support this claim.
Evidence: 172/260 (66.2%) achieved uMRD in BM vs 0/263 (0%) and 127/263 (48.3%) with p<0.001.
Within two-years, 299 participants achieved uMRD in BM: 127/263 FCR (48.3%), 0/263 ibrutinib (0%) and 172/260 ibrutinib-venetoclax (66.2%) (p<0.001).
Abstractreviewer’s wording
supportedReviewer 1
Ibrutinib-venetoclax improves progression-free survival compared to ibrutinib alone or FCR.
The HRs and 5-year PFS estimates support this claim.
Evidence: HR 0.13 (95% CI 0.08-0.21) vs FCR and 0.29 (95% CI 0.17-0.49) vs ibrutinib; 5-year PFS 93.9% vs 79.0% and 58.1%.
5-year progression-free survival was 58.1% with FCR, 79.0% with ibrutinib and 93.9% with ibrutinib-venetoclax.
Abstractreviewer’s wording
supportedReviewer 1
Ibrutinib-venetoclax improves overall survival compared to ibrutinib alone or FCR.
The HRs for OS support this claim, though the comparison vs ibrutinib has a wide CI.
Evidence: HR 0.26 (95% CI 0.13-0.50) vs FCR and 0.41 (95% CI 0.20-0.83) vs ibrutinib; 5-year OS 95.9% vs 90.5% and 86.5%.
HR for overall survival was: 0.26 (95% CI, 0.13 to 0.50) for ibrutinib-venetoclax vs FCR; 0.41 (95% CI, 0.20 to 0.83) for ibrutinib-venetoclax vs ibrutinib
Abstractreviewer’s wording
supportedReviewer 1
The unmutated IGHV subgroup benefits most from ibrutinib-venetoclax.
Subgroup analyses show larger HRs in unmutated IGHV for PFS and OS.
Evidence: HR for PFS 0.20 (95% CI 0.08-0.48) vs ibrutinib and 0.07 (95% CI 0.03-0.15) vs FCR in unmutated IGHV.
In participants with unmutated IGHV, progression-free survival was longer in patients treated with ibrutinib-venetoclax than ibrutinib alone (HR for PFS, 0.20; 95%CI, 0.08 to 0.48; Fig. 2B) or FCR (HR, 0.07; 95%CI, 0.03 to 0.15; Fig. 2B).
Resultsreviewer’s wording
supportedReviewer 2
Ibrutinib-venetoclax improves progression-free survival compared to ibrutinib and FCR.
The HRs and 5-year PFS estimates support this claim.
Evidence: HR 0.13 (95% CI 0.08-0.21) vs FCR and 0.29 (95% CI 0.17-0.49) vs ibrutinib, both p<0.001.
Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR; 0.29 (95% CI, 0.17 to 0.49, p<0.001) for ibrutinib-venetoclax vs ibrutinib
Abstractreviewer’s wording
supportedReviewer 2
Ibrutinib-venetoclax improves overall survival compared to FCR.
The HR for OS vs FCR is 0.26 (95% CI 0.13-0.50), supporting the claim.
Evidence: HR 0.26 (95% CI 0.13-0.50) for ibrutinib-venetoclax vs FCR.
HR for overall survival was: 0.26 (95% CI, 0.13 to 0.50) for ibrutinib-venetoclax vs FCR
Abstractreviewer’s wording

Premise concern: surrogate not validated for clinical benefit.

INADEQUATESurrogate endpoint
The primary endpoint for the ibrutinib-venetoclax vs ibrutinib comparison is undetectable measurable residual disease (uMRD) in bone marrow, a surrogate biomarker. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD) nor cite validated evidence linking uMRD to clinical outcomes in this context. Although the trial also reports progression-free and overall survival as secondary endpoints, the primary efficacy claim for this comparison is based on uMRD.
“The primary endpoint for ibrutinib-venetoclax vs ibrutinib was uMRD (sensitivity 10-4) in BM at two years after initiation of therapy”
Find in source
ADEQUATEEffect size
The effect sizes for the key clinical outcomes are large and clinically meaningful: 5-year PFS 93.9% vs 79.0% vs 58.1% for ibrutinib-venetoclax, ibrutinib, and FCR, respectively; HR for PFS 0.13 (95% CI 0.08-0.21) for ibrutinib-venetoclax vs FCR and 0.29 (95% CI 0.17-0.49) vs ibrutinib. Overall survival also improved with HR 0.26 (95% CI 0.13-0.50) vs FCR. These are anchored to survival outcomes and are statistically supported.
“5-year progression-free survival was 58.1% with FCR, 79.0% with ibrutinib and 93.9% with ibrutinib-venetoclax. Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR; 0.29 (95% CI, 0.17 to 0.49, p<0.001) for ibrutinib-venetoclax vs ibrutinib”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The paper cites prior studies (GLOW, CAPTIVATE, CLARITY) and explains the biological rationale for combining ibrutinib and venetoclax. It acknowledges limitations of prior work, such as fixed-duration therapy and the need for individualized approaches. The premise is well-supported by the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific rationale for the study, citing prior work on ibrutinib-venetoclax and MRD-guided therapy, and the hypothesis follows logically.

Evidence

paraphrase[Introduction, paragraph 2]

“GLOW and CAPTIVATE trials studied ibrutinib-venetoclax 15 months fixed-duration combination, leading to improved progression-free survival.”

paraphrase[Introduction, paragraph 2]

“In relapsed-refractory CLL, ibrutinib-venetoclax combination using eradication of detectable measurable residual disease (MRD) to guide duration of therapy, demonstrated that individualizing therapy was feasible.”

paraphrase[Discussion, paragraph 1]

“In FLAIR, MRD responses are more durable than reported in fixed-duration ibrutinib-venetoclax, possibly due to the personalized approach and longer exposure to ibrutinib-venetoclax.”

PASSReviewer 2· 90% conf

The introduction establishes a clear rationale for the study, citing prior work on ibrutinib-venetoclax and MRD-guided therapy, and the hypothesis follows logically.

Evidence

paraphrase[Introduction, paragraph 2]

“GLOW and CAPTIVATE trials studied ibrutinib-venetoclax 15 months fixed-duration combination, leading to improved progression-free survival.”

paraphrase[Introduction, paragraph 3]

“Here, we present the pre-planned analysis comparing MRD-guided ibrutinib-venetoclax with ibrutinib and FCR with extended follow-up.”

paraphrase[Introduction, paragraph 2]

“Continuous BTK inhibitor therapy leads to improved outcomes but can induce resistance and toxicity.”

Randomization method and unit are clearly described (computer-generated minimization, 1:1:1). Blinding is not applicable as it is an open-label trial, which is stated. Power analysis is described for the primary endpoint (O'Brien-Fleming alpha-spending) and the powered secondary endpoint (90 events). Inclusion/exclusion criteria are summarized and detailed in the appendix. Outlier handling is addressed through the pre-specified analysis population (ITT) and safety population. Controls are the comparator arms (ibrutinib and FCR). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, with a computer-generated minimization algorithm, open-label (stated), pre-specified endpoints, and a power analysis for the primary and powered secondary endpoints.

Evidence

paraphrase[Methods, Randomization and Procedures]

“Participants were randomly assigned (1:1:1) to receive FCR, ibrutinib or ibrutinib-venetoclax with the use of a computer-generated minimization algorithm with a random element.”

paraphrase[Abstract, Methods]

“In this phase III, multicenter, randomized-controlled, open-label trial”

paraphrase[Methods, Statistical Analysis]

“To ensure an overall significance level of 5% for this comparison allowing for interim analysis, the O’Brien and Fleming alpha-spending function was used. The results of the final analysis were significant if P≤0.048.”

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, open-label, with clear endpoints, statistical analysis plan, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and Procedures]

“Participants were randomly assigned (1:1:1) to receive FCR, ibrutinib or ibrutinib-venetoclax with the use of a computer-generated minimization algorithm with a random element.”

paraphrase[Methods, Statistical Analysis]

“To ensure an overall significance level of 5% for this comparison allowing for interim analysis, the O’Brien and Fleming alpha-spending function was used.”

paraphrase[Methods, Trial Design and Patients]

“Key inclusion criteria included previously untreated CLL or small lymphocytic lymphoma requiring treatment; considered fit for FCR, between 18 and 75 years of age.”

The paper reports sex (male/female), age (median and IQR), ethnicity, and other baseline characteristics in Table 1. Since both sexes are enrolled, sex_justified is not applicable. Age, weight, and health status are reported (age, performance status, creatinine clearance). Demographics are adequately reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, ethnicity, and key disease characteristics. Sex is reported for both sexes, so no single-sex justification is needed.

Evidence

“Gender Male 187 (71.1%) 186 (70.7%) 186 (71.5%) 559 (71.1%) Female 76 (28.9%) 77 (29.3%) 74 (28.5%) 227 (28.9%)”

Table 1Find in source

paraphrase[Results, Patients]

“The median age was 62 years (IQR, 56 to 67); 247 (31.4%) > 65 years.”

“Ethnicity White 240 (91.3%) 241 (91.6%) 235 (90.4%) 716 (91.1%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, ethnicity, and disease stage.

Evidence

“Gender Male 187 (71.1%) 186 (70.7%) 186 (71.5%) 559 (71.1%) Female 76 (28.9%) 77 (29.3%) 74 (28.5%) 227 (28.9%)”

Table 1Find in source

paraphrase[Table 1]

“Median Age (IQR) - yr 62 (57-67) 62 (56-67) 62 (55-67) 62 (56-67)”

“Ethnicity White 240 (91.3%) 241 (91.6%) 235 (90.4%) 716 (91.1%)”

Table 1Find in source

The paper states that a national ethics committee and institutional review boards approved the protocol, and participants provided written informed consent. Compliance with the Declaration of Helsinki is stated. This meets the criteria for human research.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval is documented: a national ethics committee and institutional review boards approved the protocol, and written informed consent was obtained. The trial was performed in accordance with the Declaration of Helsinki.

Evidence

paraphrase[Methods, Trial Design and Patients]

“A national ethics committee and institutional review boards approved the protocol.”

“Participants provided written informed consent.”

MethodsFind in source

“The trial was performed in accordance with the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

paraphrase[Methods, Trial Design and Patients]

“A national ethics committee and institutional review boards approved the protocol.”

“Participants provided written informed consent.”

MethodsFind in source

“The trial was performed in accordance with the Declaration of Helsinki.”

MethodsFind in source

The trial uses ibrutinib and venetoclax as investigational products; they are named with manufacturers (Johnson and Johnson, AbbVie) and dosing regimens. The statistical software is not explicitly named in the main text, but the analysis methods are described. Since this is a drug trial, the bench criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable. Reagents are scored against the investigational products, which are adequately identified.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational products (ibrutinib and venetoclax) are identified with manufacturer and dosing regimen, and the statistical software is identified. No other biological/chemical resources are used.

Evidence

paraphrase[Funding]

“Study drug (ibrutinib) was provided by Johnson and Johnson and study drug (venetoclax) was provided by AbbVie.”

“Ibrutinib monotherapy was administered orally 420 mg/day for six years.”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named in the main text.

PASSReviewer 2· 85% conf

The investigational products (ibrutinib and venetoclax) are identified with manufacturer and dosing, and statistical software is identified.

Evidence

paraphrase[Methods, Randomization and Procedures]

“Ibrutinib monotherapy was administered orally 420 mg/day for six years. In the ibrutinib-venetoclax group, ibrutinib was administered orally 420 mg/day for 8 weeks before venetoclax was incrementally escalated to 400 mg/day over 5 weeks.”

paraphrase[Funding]

“Study drug (ibrutinib) was provided by Johnson and Johnson and study drug (venetoclax) was provided by AbbVie.”

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

Tests are named (binary logistic penalized regression, Cox proportional hazards, Kaplan-Meier). Assumptions are handled by design (Cox model, penalized regression). Exact p-values are reported for primary and powered secondary endpoints (e.g., p<0.001). Effect sizes are reported with 95% CIs. Statistical software is not explicitly named, but this is a minor omission. Data presentation includes Kaplan-Meier curves and forest plots, which is appropriate for a clinical trial. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described: logistic regression for the primary endpoint, Cox proportional hazards for survival, Kaplan-Meier estimates, and exact p-values for primary comparisons. Effect sizes are reported with confidence intervals.

Evidence

paraphrase[Methods, Statistical Analysis]

“We made comparisons using a binary logistic penalized regression model with adjustment for the minimization factors (excluding trial center).”

paraphrase[Abstract, Results]

“172/260 ibrutinib-venetoclax (66.2%) (p<0.001)”

paraphrase[Abstract, Results]

“Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values for primary endpoints and effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical Analysis]

“We made comparisons using a binary logistic penalized regression model with adjustment for the minimization factors (excluding trial center).”

paraphrase[Abstract]

“Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR”

paraphrase[Results, Efficacy]

“HR for progression-free survival (ibrutinib-venetoclax vs. ibrutinib) was 0.29 (95%CI, 0.17 to 0.49; P<0.001)”

No data availability statement is present in the paper. The protocol is mentioned as available at NEJM.org, but this does not constitute a data availability statement for the trial data. No repository deposits or accession numbers are provided. Code sharing is not applicable as no bespoke code is described.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned. This is a reporting gap for a clinical trial.

Evidence

absence[Entire paper]

No data availability statement is present.

paraphrase[Methods, Trial Design and Patients]

“The authors designed the trial, vouch for the accuracy and completeness of the data, and adherence to the protocol (available at NEJM.org).”

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned.

Evidence

absence[Entire paper]

No data availability statement is present.

Trial registration numbers are provided. Methods are detailed enough for replication. Limitations are discussed (e.g., open-label design, cross-trial comparisons, need for longer follow-up). Conclusions are proportional to the evidence. Funding sources and conflicts of interest are disclosed. Reporting guidelines are not explicitly mentioned, but the paper follows CONSORT-like structure.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered (ISRCTN01844152, EudraCT 2013-001944-76), methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

paraphrase[Abstract, Conclusion]

“FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.”

paraphrase[Discussion, paragraph 4]

“These findings should also be interpreted in the context of the relatively young trial population, in whom longer term follow up is essential to evaluate the potential for functional cure.”

“Primary financial support was from Cancer Research UK (C18027/A15790).”

FundingFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

paraphrase[Abstract]

“FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.”

paraphrase[Discussion, paragraph 5]

“These findings should also be interpreted in the context of the relatively young trial population, in whom longer term follow up is essential to evaluate the potential for functional cure.”

“Primary financial support was from Cancer Research UK (C18027/A15790).”

FundingFind in source

Registered (2 IDs: ISRCTN). No reporting guideline cited.

ISRCTN

ISRCTN01844152

ISRCTN

ISRCTN51675454

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 20 references by DOI: 18 verified — 2 no DOI (shown, not verified).

NO DOI
U.S. Population Data 1969 - 2022 with Other Software
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
A multiple testing procedure for clinical trials
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

Copyediting

13 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 13 minor suggestions below.

13 copyedit issues flagged: mostly typo, consistency.

MINORtypoAbstract, Results
“1 27 /263 FCR ( 48 . 3 %)”
→ Remove extra spaces: '127/263 FCR (48.3%)'
Spacing errors in numbers.
MINORtypoAbstract, Results
“0 /263 ibrutinib (0%)”
→ Remove extra spaces: '0/263 ibrutinib (0%)'
Spacing error.
MINORtypoAbstract, Results
“1 72 /260 ibrutinib - venetoclax ( 66.2 %)”
→ Remove extra spaces: '172/260 ibrutinib-venetoclax (66.2%)'
Spacing error.
MINORtypoAbstract, Results
“0. 64 (95% CI, 0. 39 to 1.05 )”
→ Remove extra spaces: '0.64 (95% CI, 0.39 to 1.05)'
Spacing error.
MINORconsistencyResults, Safety
“Eleven deaths were seen in participants treated with ibrutinib-venetoclax, 25 with ibrutinib and 37 with FCR”
→ Ensure consistency with earlier death counts (11, 26, 39) and Table S23.
Potential inconsistency in death counts.
MINORtypoSupplementary Table S20
“53 (115.2%)”
→ Check percentage calculation; 115.2% is impossible.
Percentage exceeds 100%.
MINORtypoSupplementary Table S21
“29 (120.8%)”
→ Check percentage calculation; 120.8% is impossible.
Percentage exceeds 100%.
MINORconsistencyResults, Safety
“742 of 756 (98.1%) in the safety population reported at least one adverse event.”
→ Verify safety population total (756) vs. sum of group sizes (239+260+257=756).
Safety population total is consistent.
MINORtypoReferences
“0.1056/nejm200012283432602.”
→ Remove stray DOI fragment.
Stray text at end of references.
MINORtypoAbstract, Results
“1 27 /263 FCR ( 48 . 3 %)”
→ 127/263 FCR (48.3%)
Spacing and formatting inconsistency.
MINORconsistencyResults, Efficacy
“0/263 ibrutinib (0%)”
→ 0/263 ibrutinib (0%)
Consistent formatting of fractions.
MINORtypoResults, Safety
“70 / 25 7 [ 27.2 %]”
→ 70/257 [27.2%]
Spacing issue.
MINORconsistencyTable 2
“FCR (n=239) I (n=260) I+V (n=257)”
→ Ensure consistent use of n vs N.
Minor inconsistency in capitalization.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and the main conclusions are supported by the reported analyses. An informed reader should weigh the missing data availability statement and the minor internal inconsistencies (death counts, impossible percentages) as reporting gaps that warrant correction or clarification, but they do not undermine the primary efficacy findings.

1.
HIGHrigor
Reconcile the death counts: the Safety section states 'Eleven deaths were seen in participants treated with ibrutinib-venetoclax, 25 with ibrutinib and 37 with FCR' (sum 73), conflicting with the abstract and Results which report 11, 26, and 39 (sum 76). Correct the inconsistent numbers in the Safety section or elsewhere.
An internal contradiction in a key safety outcome is a validity threat that could mislead readers and warrants a correction.
2.
HIGHrigor
Correct the impossible percentages in Supplementary Tables S20 and S21 (e.g., 115.2% and 120.8%) which exceed 100% for a proportion.
Impossible statistics indicate a calculation or reporting error that undermines the credibility of the supplementary data.
3.
HIGHdata code
Add a data availability statement to the manuscript (e.g., in Methods or a dedicated section) specifying how de-identified patient data can be accessed (e.g., via a data access committee or repository like YODA/Vivli) and the conditions for access.
The absence of a data availability statement is a reporting gap for a clinical trial and is required by most journals and funders.
4.
HIGHstatistics
Explicitly name the statistical software used (e.g., SAS, R) with version numbers in the Statistical Analysis section.
Identifying the software is essential for reproducibility and is a standard reporting requirement.
5.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or a separate section, and provide the checklist as supplementary material.
Explicitly referencing CONSORT improves transparency and is expected for randomized trials.
6.
MEDIUMcopyedit
Fix the spacing errors in the Abstract Results (e.g., '1 27 /263 FCR ( 48 . 3 %)' should be '127/263 FCR (48.3%)', '1 72 /260 ibrutinib - venetoclax ( 66.2 %)' should be '172/260 ibrutinib-venetoclax (66.2%)', '0. 64 (95% CI, 0. 39 to 1.05 )' should be '0.64 (95% CI, 0.39 to 1.05)').
Spacing errors in key results detract from professionalism and readability.
7.
MEDIUMcopyedit
Remove the stray DOI fragment at the end of the References ('0.1056/nejm200012283432602.').
Stray text in references is a formatting error that should be corrected.
8.
MEDIUMcopyedit
Ensure consistent formatting of fractions and percentages throughout the manuscript (e.g., '70 / 25 7 [ 27.2 %]' should be '70/257 [27.2%]').
Consistent formatting improves clarity and avoids confusion.
9.
LOWcopyedit
Standardize the use of 'n' vs 'N' in Table 2 (e.g., 'FCR (n=239) I (n=260) I+V (n=257)').
Minor capitalization inconsistency is a polish issue.
10.
LOWdata code
Consider depositing the statistical analysis code (if any) in a public repository with a DOI to enhance reproducibility.
Sharing analysis code would strengthen reproducibility, though it is not mandatory.
11.
LOWreporting
Clarify the availability of the trial protocol and statistical analysis plan (e.g., at NEJM.org) in a dedicated statement.
Providing a clear link to the protocol and SAP improves transparency.

Full text (132,334 chars · analyzed ~57%, head + tail)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

DOI

10.1056/NEJMoa2504341

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-21